VIA Pharmaceuticals, Inc.
VIAP
Rank in Stocks
#34460
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Share Price
$0.0005
Last synced: 2026-11-10
Market Cap
$10.23K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade VIA Pharmaceuticals, Inc. (VIAP)
Category
Healthcare
Operating Margin for VIA Pharmaceuticals, Inc. (VIAP)
Operating Margin as of November 2026 TTM: 0.00%
According to VIA Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2010 the company had an operating margin of 0.00%.
Operating Margin history for VIA Pharmaceuticals, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | -100.00% |
| 2006 | -9,868.14% | -58.39% |
| 2005 | -23,715.45% | 93.92% |
| 2004 | -12,229.53% | -86.01% |
| 2003 | -87,443.09% | 8,334.27% |
| 2002 | -1,036.76% | -73.70% |
| 2001 | -3,942.11% | -37.98% |
| 2000 | -6,355.79% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 62.34% | - |
US
|
|
| 31.60% | - |
SE
|
|
| 30.13% | - |
FR
|
|
| 29.76% | - |
HK
|
|
| 30.46% | - |
IT
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about VIA Pharmaceuticals, Inc.'s operating margin
What was VIA Pharmaceuticals, Inc.'s operating margin in 2010?
In 2010, VIA Pharmaceuticals, Inc.'s operating margin was 0.00%, compared with 0.00% in 2009.
How has VIA Pharmaceuticals, Inc.'s operating margin changed since 2005?
From 2005 to 2010, VIA Pharmaceuticals, Inc.'s operating margin was highest in 2010 (0.00%) and lowest in 2005 (-23,715.45%).
How does VIA Pharmaceuticals, Inc.'s operating margin compare with similar companies?
VIA Pharmaceuticals, Inc.'s operating margin (0.00%) is lower than that of all 5 similar companies listed above. The highest among them is Royalty Pharma plc, with 62.34%.